NCT03401840

STEREO-POSTOP 01 (PostOperative Hypofractionated Stereotactic Body Radiotherapy ) - GORTEC 2017-03

A Multicenter Prospective Phase II Study of Postoperative Hypofractionated Stereotactic Body Radiotherapy (SBRT) in the Treatment of Early Stage Oropharyngeal and Oral Cavity Cancers With High Risk Margins.

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 90 (actual)
• Sponsor: Centre Jean Perrin · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The main objective of this national, open-label, non-randomized phase II trial is to evaluate severe late toxicity of postoperative hypofractionated stereotactic radiotherapy (SBRT) in the treatment of early stage oropharyngeal and oral cavity cancer with high risk margins.

Conditions

• Head and Neck Neoplasms

Interventions

Type	Name	Description
RADIATION	postoperative hypofractionated stereotactic radiotherapy	total dose of 36Gy in 6 fractions over 11-13 days

Timeline

• Start date: 2018-01-23
• Primary completion: 2023-09-28
• Completion: 2023-09-28
• First posted: 2018-01-17
• Last updated: 2025-02-13

Locations

24 sites across 1 country: France